课题基金 / 基金详情

The foundations of specific radiobiological effects generated by laser-accelerated protons

The foundations of specific radiobiological effects generated by laser-accelerated protons
激光加速质子产生的特定放射生物学效应的基础
批准号:
401832363
负责人:
Professor Dr. Friedrich Boege
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2018
资助国家:
德国
项目状态:
已结题
起止时间:
2017-12-31 至 2021-12-31

项目摘要

项目成果

Professor Dr. Friedrich Boege的其他基金

相似基金

相关文献

中文摘要
翻译
目前,主流放射治疗(RT)主要使用x射线,显示不利的能量沉积模式,用于深部肿瘤。能量带电粒子形式的红外对肿瘤中的能量沉积模式提供了重大改进。然而,粒子疗法的推广目前受到高成本和资源占用的阻碍。尽管有这些限制,粒子RT在世界范围内得到了大力的追求,德国与几个先进的质子和重离子治疗中心共同引领了这一发展。与此同时,新型带电粒子加速技术发展出了成本更低、占地面积更小的粒子发生器,因此有望在临床试验中广泛分布和可行性。本应用程序旨在研究一种带电粒子加速技术的放射生物学效应:基于激光尾迹场加速原理的激光驱动等离子体加速。德<s:1>塞尔多夫大学在这一领域进行了大量投资,O. Willi教授操作着一个200太瓦的激光系统,专门用于产生激光加速质子(LAP),这是拟议研究的基础。位于埃森大学诊所的西德埃森质子中心(WPE)由B. Timmermann教授提供所需的参考质子束(CAP)。LAP的放射生物学尚处于起步阶段,相关信息现在才开始出现。在埃森大学诊所G. Iliakis教授的领导下,我们的研究小组已经合作了几年,研究LAP的放射生物学效应,并取得了开创性的发现,为拟议的研究奠定了基础。该提案测试了LAP表现出不同放射生物学的假设,因为每个脉冲都以皮秒波列传递,并且由一个大而密集的离子簇组成,粒子间距离非常短。结果达到了109戈瑞/秒量级的剂量率,比回旋加速器所达到的剂量率高出9-11个数量级。由此可见,尽管LAP和CAP类似地引起水辐射溶解并产生短暂的初级自由基,但它们的生化和生物学后果不同,我们发现通过与no依赖途径相互作用,3-硝基酪氨酸的产量较低。德国<s:1>塞尔多夫大学的C. Suschek教授阐明了这种差异的机制基础。自由基生成平衡的变化将改变由直接/间接影响以及细胞应激反应产生的DNA损伤类型。F. Boege教授和G. Iliakis教授对LAP的这些方面进行了深入的研究,重点是产生的DNA双链断裂的形式和细胞对它们的反应。提出的工作解决了LAP生物学的核心问题,为它们在临床中的未来应用做准备,并有助于增强德国在国际粒子治疗领域的明确优势。
英文摘要
Current, mainstream Radiation Therapy (RT) predominantly utilizes X-rays that show unfavorable energy deposition patterns for deep-seated tumors. Energetic-charged-particle forms of IR offer major improvements in the energy deposition patterns in a tumor. Yet, the spreading of particle therapy is currently impeded by the high cost and resource footprint. Despite such limitations particle RT is emphatically pursued worldwide and Germany co-leads this development with several advanced proton and heavy ion therapy centers. In parallel, novel charged-particle acceleration technologies evolve promising particle generators at lower cost and smaller footprint, thus promising wide distribution and feasibility for clinical trials. The present application is designed to study the radiobiological effects of one such charged-particle acceleration technology: Laser-driven, plasma-acceleration, based on laser wake-field acceleration principles. The University of Düsseldorf has made large investments in this field and Professor O. Willi operates a 200 TW laser system dedicated to the production of laser-accelerated protons (LAP) that is the basis of the proposed research. The West German Proton Center Essen (WPE) at the University Clinics Essen under Prof. B. Timmermann provides the required reference proton beams (CAP). The radiobiology of LAP is at its infancy and relevant information is only now beginning to emerge. Our consortium under the leadership of Prof. G. Iliakis at the University Clinics Essen, has cooperated for several years to study the radiobiological effects of LAP and has made seminal discoveries underpinning the proposed studies. The proposal tests the hypothesis that LAP exhibit different radiobiology because each pulse is delivered in picosecond wave-trains and consists of a large, dense ion cluster with very short inter-particle distances. As a result dose rates in the order of 109 Gy/sec are reached that are up to 9-11 orders of magnitude greater than those achieved by a cyclotron. It follows that although LAP and CAP are similarly causing water radiolysis and generate short-lived primary radicals, their biochemical and biological consequences differ as indicated by our discovery of lower production of 3-nitrotyrosine through interaction with NO-dependent pathways. Prof. C. Suschek at the University of Düsseldorf elucidates the mechanistic underpinnings of such differences. Changes in the balance of radical production will modify the type of DNA damage generated by direct/indirect effects, as well cellular stress responses. These aspects of LAP are investigated in depth by Prof. F. Boege and Prof. G. Iliakis focusing on forms of DNA double strand breaks generated and the cellular responses to them. The proposed work addresses central questions of the biology of LAP, prepares their future application in the clinic and helps to enhance the clear edge of Germany in the field of particle therapy internationally.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
REDOX-regulation of mitochondrial transcription by mitochondrial DNA topoisomerase I
Analyse kovalenter DNS-Intermediate von Topoisomerasen und Rekombinasen mittels Antikörper gegen Tyrosin-Nukleinsäure-Phosphodiester
Topoisomerase I-vermittelter Gentransfer in humane Zellen. Selbständige Entwicklung einer gentherapeutisch anwendbaren Methode zur Patentreife
Targeting of DNA-Topoisomerase-II by protein-protein interactions
国内基金
海外基金
新生儿坏死性小肠结肠炎中去泛素化酶USP15调控ILC3分化损伤肠道粘膜屏障的致病机制研究
  • 批准号:
    82371711
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    吕志宝
  • 依托单位:
人巨细胞病毒编码蛋白UL23调控 HCMV-specific T 细胞增殖、活性及分化的机理
  • 批准号:
    32070149
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    李弘剑
  • 依托单位:
花胶鱼类物种Species-specific PCR和Multiplex PCR鉴定体系研究
  • 批准号:
    31902373
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    23.0万元
  • 批准年份:
    2019
  • 负责人:
    曾玲
  • 依托单位:
Dravet综合征基因突变分析及突变来源研究
  • 批准号:
    81171221
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2011
  • 负责人:
    张月华
  • 依托单位: